Rallybio Corporation (NASDAQ: RLYB)
$1.45
+0.1100 ( +8.21% ) 154.6K
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Market Data
Open
$1.45
Previous close
$1.34
Volume
154.6K
Market cap
$60.10M
Day range
$1.32 - $1.46
52 week range
$1.16 - $6.38
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | May 21, 2024 |
4 | Insider transactions | 1 | May 17, 2024 |
4 | Insider transactions | 1 | May 17, 2024 |
4 | Insider transactions | 1 | May 17, 2024 |
4 | Insider transactions | 1 | May 17, 2024 |
4 | Insider transactions | 1 | May 17, 2024 |
4 | Insider transactions | 1 | May 17, 2024 |
4 | Insider transactions | 1 | May 17, 2024 |
4 | Insider transactions | 1 | May 17, 2024 |
10-q | Quarterly Reports | 63 | May 09, 2024 |